Michael Geffner - Jan 16, 2024 Form 3 Insider Report for Immunovant, Inc. (IMVT)

Role
Chief Medical Officer*
Signature
/s/ Eva Renee Barnett, attorney-in-fact for Michael Geffner
Stock symbol
IMVT
Transactions as of
Jan 16, 2024
Transactions value $
$0
Form type
3
Date filed
1/16/2024, 07:29 AM
Next filing
Jan 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IMVT Common Stock 100K Jan 16, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMVT Stock Option (right to buy) Jan 16, 2024 Common Stock 150K $18.06 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares underlying restricted stock units awards ("RSUs").
F2 On January 17, 2023, the holder was granted 100,000 RSUs. The RSUs vest over four years, with 25% of the RSUs vesting on January 17, 2024 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.
F3 On January 17, 2023, the holder was granted 150,000 stock options. Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on January 17, 2024 and the remainder of the shares underlying the options vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Remarks:

* The Issuer's Board of Directors appointed the Reporting Person as a Chief Medical Officer of the Issuer effective January 16, 2024. William Macias, M.D. will remain with the Issuer as a Chief Medical Officer. The Reporting Person and Dr. Macias will share Chief Medical Officer responsibilities as the Issuer expands its scope of clinical development activities. In addition, refer to Exhibit 24 - Power of Attorney.